CN101891690B - Synthesis method of N-substituted-4-amino-quinazoline compound - Google Patents
Synthesis method of N-substituted-4-amino-quinazoline compound Download PDFInfo
- Publication number
- CN101891690B CN101891690B CN2010102120353A CN201010212035A CN101891690B CN 101891690 B CN101891690 B CN 101891690B CN 2010102120353 A CN2010102120353 A CN 2010102120353A CN 201010212035 A CN201010212035 A CN 201010212035A CN 101891690 B CN101891690 B CN 101891690B
- Authority
- CN
- China
- Prior art keywords
- quinazoline
- substituted
- amino
- formula
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The invention discloses a synthesis method of N-substituted-4-amino-quinazoline compound, which comprises the steps of: mixing quinazoline-4 (3H)-ketone compound shown in formula (II), amine compound shown in formula (III) and hexamethyl disilazane according to the molar ratio of 1 to 1-2.5 to 1-2.5; adding catalyst ammonium sulfate, stirring under the protection of nitrogen, and heating to 105-125 DEG C for reaction; carrying out TLC monitoring until complete reaction; and after the reaction, treating reactant by separation and obtaining the N-substituted-4-amino-quinazoline compound. The synthesis method has simple and short synthetic route, simple and safe operation, no need for solvent in the reaction, high product yield, low synthesis cost and higher implementation valve as well as social and economical benefits.
Description
(1) technical field
The present invention relates to a kind of compound method of N-substituted-4-amino-quinazoline compound, the method for the synthetic N-substituted-4-amino-quinazoline compound of particularly a kind of one kettle way.
(2) background technology
The N-substituted-4-amino-quinazoline compound has physiologically active widely, has become one of research focus of new drug development initiative at present.For example, 6,7,8-trimethoxy-N-aryl-4-amido quinazoline derivatives to tumour cells such as PC3, A431, Bcap-37 and GC823 have inhibiting (Bioorg.Med.Chem.2007,15:6608-6617); 5-replacement-4-aniline quinazoline derivative be the erbB2 receptor tyrosine kinase effective suppressor factor (Bioorg.Med.Chem.Lett.2008,18:674-678); The cyclosubstituted 4-amido quinazoline derivatives of the last pyrazoles of N, as Aurora B SU11752 have activity (J.Med.Chem.2007,50,2213-2224).In recent years; The medicine of some tool N-substituted-4-amino quinazoline structures; For example: ZD1939 (Gefitinib); Erlotinib (Erlotinib), xylene monosulfonic acid lapatinibditosylate (Lapatinib ditosylate), the card knob is for all listings successively such as Buddhist nun's dihydrochlorides (Canertinibdihydrochloride).
The compound method of traditional N-substituted-4-amino-quinazoline compound is to be raw material with quinazoline-4 (3H)-ketone compounds; Obtain 4-chloro-quinazoline compounds through chlorination reaction; Under alkalescence or acidic conditions, S takes place in 4-chloro-quinazoline compounds and aminated compounds
NThe Ar substitution reaction obtains the N-substituted-4-amino-quinazoline compound.Mainly there is following shortcoming in this route: 1) chlorination reagent generally is SOCl
2, POCl
3Or PCl
5, environment friendly is poor; 2) the chlorination reagent consumption that uses in the chlorination reaction is too much, causes wastage of material, the aftertreatment difficulty; 3) intermediate product 4-chloro-quinazoline compounds activity is higher, and the conditional request of prolonged preservation is high; 4) two-step reaction, yield are not high.
(3) summary of the invention
The objective of the invention is to overcome the various shortcomings of prior art, the route method of the synthetic N-substituted-4-amino-quinazoline compound of an one kettle way that route is simple, easy and simple to handle, reaction yield is high is provided.
The technical scheme that the present invention adopts is following:
A kind of compound method suc as formula the N-substituted-4-amino-quinazoline compound shown in (I); Described method is: is 1: 1～2.5: 1～2.5 to mix suc as formula quinazoline-4 (the 3H)-ketone compounds shown in (II), suc as formula the aminated compounds shown in (III) and hexamethyldisilazane with the ratio of amount of substance; Add the catalyst sulfuric acid ammonium; Be heated with stirring to 105 ℃～125 ℃ under the nitrogen protection and react, the TLC monitoring is to reacting completely, and the reaction times is 0.5～20 hour usually; After reaction finished, reactant obtained described N-substituted-4-amino-quinazoline compound through separating treatment;
In formula (I) or the formula (II), the benzene ring hydrogen is substituted basic R
1Replace or be not substituted described substituent R
1Be alkyl or the C1～C3 alkoxyl group of halogen, nitro, C1～C4, said halogen is F, Cl, Br or I; R
2Be H, methyl or ethyl; In formula (I) or the formula (III), R
3For on the benzyl, α-Jia Bianji, 4 or 5 the 1H-pyrazole-3-yl of the alkyl substituent of C1～C4, the alkyl of C4～C10 or the naphthenic base of C5～C8 are arranged.
Comparatively preferred, said R
1Be methyl, F, Cl, Br, nitro, methoxy or ethoxy.
Said R
2Be preferably H or methyl.
Said R
3Be preferably benzyl, α-Jia Bianji, 5-methyl isophthalic acid H-pyrazole-3-yl, 4-methyl isophthalic acid H-pyrazole-3-yl, normal-butyl, isobutyl-, n-hexyl, n-octyl, cyclopentyl or cyclohexyl.
Said is 1: 1～2.5: 1～2.5 suc as formula quinazoline-4 (the 3H)-ketone compounds shown in (II), suc as formula the aminated compounds shown in (III) and hexamethyldisilazane with the ratio of amount of substance, preferred 1: 1.4～2: 1.4～2.
The amount of substance ratio of the amount of substance of said catalyst sulfuric acid ammonium and quinazoline-4 (3H)-ketone compounds is 5～20: 100, preferred 8～12: 100.
Said temperature of reaction is 105 ℃～125 ℃, is preferably 120～125 ℃.
The said reaction times is generally 0.5～20h, is preferably 1.5～14 hours.
Said reactants separate treatment process is: after reaction finishes; Reactant is cooled to room temperature, adds methylene dichloride solubilizing reaction thing, carries out column chromatography for separation; Do eluent with sherwood oil and 5: 1 blended mixed solutions of ETHYLE ACETATE volume ratio; TLC detects, and collects the elutriant that contains the N-substituted-4-amino-quinazoline compound, and the elutriant distillation is removed eluent and obtained described N-substituted-4-amino-quinazoline compound.
Comparatively concrete, recommend method of the present invention to carry out according to following steps: is 1: 1.4～2: 1.4～2 to mix suc as formula quinazoline-4 (the 3H)-ketone compounds shown in (II), suc as formula the aminated compounds shown in (III) and hexamethyldisilazane with the ratio of amount of substance, adds ammonium sulfate; The ratio of described ammonium sulfate and quinazoline-4 (3H)-ketone compounds amount of substances is 8～12: 100; Be heated with stirring to 120～125 ℃ under the nitrogen protection and react, TLC monitors to reacting completely, and reacts 1.5～14h usually; After reaction finishes; Reactant is cooled to room temperature, adds methylene dichloride solubilizing reaction thing, carries out column chromatography for separation; 5: 1 blended mixed solutions of volume ratio with sherwood oil and ETHYLE ACETATE are cooked eluent; TLC detects, and collects the elutriant that contains the N-substituted-4-amino-quinazoline compound, and the elutriant distillation is removed eluent and obtained described N-substituted-4-amino-quinazoline compound.
The present invention compared with prior art, its beneficial effect is embodied in: it is low to need not high, the synthetic cost of solvent, product yield in brief, simple to operate safe, the reaction of this synthetic route, has bigger implementary value and economic results in society.
(4) embodiment
Through embodiment the present invention is described further below, but protection scope of the present invention is not limited to this.
The structural formula of the prepared N-substituted-4-amino-quinazoline compound of following embodiment is respectively suc as formula shown in (1)～(16):
The preparation of embodiment 1:N-benzyl-4-amido quinazoline (formula (1))
, the reactor drum of magneton adds 0.4mmol quinazoline-4 (3H)-ketone, the benzylamine of 0.56mmol, the hexamethyldisilazane of 0.56mmol and the ammonium sulfate of 0.04mmol, the following 125 ℃ of stirring reactions of nitrogen protection in being arranged; The TLC monitoring, reaction 2h reacts completely, and reaction finishes; Reaction mixture is cooled to room temperature, adds 5mL methylene dichloride solubilizing reaction thing, directly upper prop; Mixed solution (v/v, 5: 1) with sherwood oil and ETHYLE ACETATE is cooked eluent, and TLC detects; Collection contains the elutriant of product, and the elutriant distillation is removed eluent and obtained title product, and yield is 97%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.71(s，1H)，7.86(d，1H)，7.71-7.76(m，2H)，7.31-7.47(m，6H)，6.07(br，s，1H)，4.88(d，2H)；
13C?NMR(CDCl
3)δppm：159.45，155.5，149.5，138.1，132.8，1298.0，128.79，128.1，127.9，126.2，120.6，114.9，45.4；
MS(ESI)m/z：235.6[M+H
+]；
IR?v
max(KBr)/cm
-1?3228，3060，2966，2935，1619，1575，1541，1495，1415，1340。
The preparation of embodiment 2:N-benzyl-4-amido quinazoline (formula (1))
Reactions step is with embodiment 1, and different is that temperature of reaction is 105 ℃, and the reaction times is 5h, and product yield is 56%.
The preparation of embodiment 3:N-benzyl-4-amido quinazoline (formula (1))
Reactions step is with embodiment 1, and the consumption of different is benzylamine and hexamethyldisilazane is 0.40mmol, and product yield is 81%.
The preparation of embodiment 4:N-benzyl-4-amido quinazoline (formula (1))
Reactions step is with embodiment 1, and the consumption of different is ammonium sulfate is 0.02mmol, and product yield is 81%.
The preparation of embodiment 5:N-benzyl-4-amino-5-methyl quinazoline (formula (2))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 5-methyl quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 14h, and product is a yield 88%.
This compound
1H NMR,
13The data of C NMR, HRMS and IR are described below:
1H?NMR(CDCl
3)δppm：8.61(s，1H)，7.71(d，1H)，7.55-7.58(m，1H)，7.31-7.43(m，5H)，7.20(d，1H)，6.35(br，s，1H)，4.85(d，2H)，2.84(s，1H)；
13C?NMR(CDCl
3)δppm：160.7，154.6，151.5，138.2，132.8，131.9，129.2，128.9，127.8，127.7，127.0，115.5，46.0，24.3；
HRMS(ESI)m/z：250.1332(M+H
+)，calcd.for?C
16H
15N
3+H
+＝250.1339；
IR?v
max(KBr))/cm
-1?3498，3060，3029，2924，2872，1578，1524，1349。
The preparation of embodiment 6:N-benzyl-4-amino-6-methyl quinazoline (formula (3))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 6-methyl quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 2h, and product is a yield 95%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.67(s，1H)，7.77(d，1H)，7.56-7.58(m，1H)，7.46(s，1H)，7.33-7.43(m，5H)，5.93(br，s，1H)，4.87(d，2H)，2.49(s，3H)；
13C?NMR(CDCl
3)δppm：159.0，154.7，147.8，138.3，136.2，134.6，128.9，128.4，128.1，127.8，119.8，114.7，45.4，21.7；
MS(ESI)m/z：250.1(M+H
+)；
IR?v
max(KBr)/cm
-1?3275，1584，1538，1420，1352，1314。
The preparation of embodiment 7:N-benzyl-4-amino-8-methyl quinazoline (formula (4))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 8-methyl quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 4.5h, and product is a yield 92%.
This compound
1H NMR,
13The data of C NMR, HRMS and IR are described below:
1H?NMR(CDCl
3)δppm：8.78(s，1H)，7.60(d，1H)，7.54(d，1H)，7.32-7.42(m，6H)，5.96(br，s，1H)，4.87(d，2H)，2.71(s，3H)；
13C?NMR(CDCl
3)δppm：159.7，154.4，148.5，138.2，136.9，132.9，128.9，128.0，127.8，125.6，118.1，114.6，45.5，18.0；
HRMS(ESI)m/z：250.1353(M+H
+)，calcd.for?C
16H
15N
3+H
+＝250.1339；
IR?v
max(KBr)/cm
-1?3250，3126，2935，1585，1531，1492，1417，1357，1329。
The preparation of embodiment 8:N-benzyl-4-amino-5-chloro-quinazoline (formula (5))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 5-chloro-quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 2h, and product yield is 93%.
This compound
1H NMR,
13The data of C NMR, HRMS and IR are described below:
1H?NMR(CDCl
3)δppm：8.61(s，1H)，8.04(br，s，1H)，7.75-7.76(m，1H)，7.57(t，1H)，7.30-7.43(m，6H)，4.86(d，2H)；
13C?NMR(CDCl
3)δppm：158.9，155.4，152.2，137.8，131.9，128.8，128.5，128.2，128.1，127.7，127.6，113.1，45.8；
HRMS(ESI)m/z：270.0793(M+H
+)，calcd.for?C
15H
12ClN
3+H
+＝270.0793；
IR?v
max(KBr)/cm
-1?3430，3059，3026，2925，1606，1577，1533，1484，1401，1341。
The preparation of embodiment 9:N-benzyl-4-amino-6-chloro-quinazoline (formula (6))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 6-chloro-quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 3h, and product yield is 93%.
This compound
1H NMR,
13The data of C NMR, HRMS and IR are described below:
1H?NMR(CDCl
3)δppm：8.69(s，1H)，7.81(d，1H)，7.66-7.68(m，2H)，7.32-7.42(m，5H)，5.91(br，s，1H)，4.86(d，2H)；
13C?NMR(CDCl
3)δppm：158.5，155.6，148.1，137.8，133.4，131.5，130.3，128.9，128.1，127.9，120.1，115.6，45.5；
HRMS(ESI)m/z：270.0793(M+H
+)，calcd.for?C
15H
12ClN
3+H
+＝270.0792；
IR?v
max(KBr)/cm
-1?3232，3101，3072，2964，1572，1542，1493，1418，1340，1324。
The preparation of embodiment 10:N-benzyl-4-amino-7-chloro-quinazoline (formula (7))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 7-chloro-quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 2h, and product yield is 95%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.68(s，1H)，7.84(d，1H)，7.65(d，1H)，7.31-7.40(m，6H)，6.07(br，s，1H)，4.86(d，2H)；
13C?NMR(CDCl
3)δppm：159.2，156.4，150.4，138.8，137.8，128.9，128.1，127.9，127.7，126.9，122.2，113.2，45.45；
MS(ESI)m/z：270.1(M+H
+)；
IR?v
max(KBr)/cm
-1?3444，3217，3101，3028，2964，1609，1570，1540，1446，1338。
The preparation of embodiment 11:N-benzyl-4-amino-7-fluquinconazole quinoline (formula (8))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 7-chloro-quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 2h, and product yield is 92%.
This compound
1H NMR,
13The data of C NMR, HRMS and IR are described below:
1H?NMR(CDCl
3)δppm：8.68(s，1H)，7.72-7.75(m，1H)，7.48-7.50(m，1H)，7.31-7.42(m，5H)，7.18-7.22(m，1H)，6.02(br，s，1H)，4.87(d，2H)；
13C?NMR(CDCl
3)δppm：165.4，163.4，159.2，156.2，151.3，151.2，139.2，128.3，127.2，126.8，126.0，125.9，115.1，114.4，112.0，111.5，111.3，43.6；
HRMS(ESI)m/z：254.1096(M+H
+)，calcd.for?C
15H
12FN
3+H
+＝254.1088；
IR?v
max(KBr)/cm
-1?3240，3074，3030，2935，1627，1579，1544，1458，1340。
The preparation of embodiment 12:N-benzyl-4-amino-6-nitro-quinazoline (formula (9))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 6-nitro-quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 1.5h, and product yield is 95%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.81(s，1H)，8.71(d，1H)，8.50-8.53(m，1H)，7.96(d，1H)，7.37-7.45(m，5H)，6.28(br，s，1H)，4.92(d，2H)；
13C?NMR(DMSO-d
6)δppm：160.2，158.2，152.8，144.1，138.6，129.1，128.4，127.5，127.0，126.3，120.6，114.0，43.9；
MS(ESI)m/z：281.1(M+H
+)；
IR?v
max(KBr)/cm
-1?3234，3084，3028，2929，1625，1585，1495，1446，1328。
The preparation of embodiment 13:N-benzyl-4-amino-6-nitro-quinazoline (formula (9))
Reactions step is with embodiment 12, and different is is 0.5h in the reaction times, and product yield is 75%.
The preparation of embodiment 14:N-normal-butyl-4-amido quinazoline (formula (10))
Reactions step is with embodiment 1, and different is that benzylamine changes n-Butyl Amine 99 into, and the consumption of reactant is constant, and the reaction times is 1.5h, and product yield is 95%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.67(s，1H)，7.84(d，1H)，7.68-7.76(m，2H)，7.46-7.49(m，1H)，5.67(br，s，1H)，3.65-3.69(m，2H)，1.72-1.75(m，2H)，1.47-1.51(m，2H)，1.00(t，3H)；
13C?NMR(CDCl
3)δppm：159.5，155.5，149.4，132.5，128.6，125.9，120.5，115.0，41.2，31.5，20.3，13.9；
MS(ESI)m/z：202.1(M+H
+)；
IR?v
max(KBr)/cm
-1?3258，3129，2959，2922，2855，1619，1578，1543，1470，1422，1348，1325。
The preparation of embodiment 15:N-n-octyl-4-amido quinazoline (formula (11))
Reactions step is with embodiment 1, and different is that benzylamine changes NSC 9824 into, and the consumption of reactant is constant, and the reaction times is 2h, and product yield is 95%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.67(s，1H)，7.84(d，1H)，7.71-7.74(m，2H)，7.44-7.47(m，1H)，5.90(br，s，1H)，3.64-3.68(m，2H)，1.72-1.75(m，2H)，1.26-1.45(m，10H)，0.88(t，3H)；
13C?NMR(CDCl
3)δppm：159.5，155.4，149.2，132.5，128.4，126.0，120.5，114.9，41.5，31.8，29.4，29.3，29.2，27.1，22.6，14.1；
MS(ESI)m/z：258.2(M+H
+)；
IR?v
max(KBr)/cm
-1?3221，2956，2927，2854，1581，1542，1498，1356，1326。
The preparation of embodiment 16:N-n-octyl-4-amido quinazoline (formula (11))
Reactions step is with embodiment 15, and different is that temperature of reaction is 120 ℃, and the reaction times is 5h, and product yield is 94%.
The preparation of embodiment 17:N-cyclohexyl-4-amido quinazoline (formula (12))
Reactions step is with embodiment 1, and different is that benzylamine changes hexahydroaniline into, and the consumption of hexahydroaniline and hexamethyldisilazane is 0.8mmol, and the reaction times is 14h, and product yield is 92%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.65(s，1H)，7.83(d，J＝8.5Hz，1H)，7.68-7.74(m，2H)，7.44-7.47(m，1H)，5.61(d，J＝7Hz，1H)，4.24-4.30(m，1H)，2.14-2.17(m，2H)，1.79-1.83(m，2H)，1.69-1.73(m，1H)，1.46-1.55(m，2H)，1.25-1.35(m，3H)；
13C?NMR(CDCl
3)δppm：158.67，155.47，149.38，132.43，128.48，125.79，120.42，114.92，49.65，33.06，25.66，24.94；
MS(ESI)m/z：227.6(M+H
+)；
IR?v
max(KBr)/cm
-1?3450，3235，3058，2932，2854，1617，1579，1535，1497，1426，1362，1323。
The preparation of embodiment 18:N-cyclohexyl-4-amido quinazoline (formula (12))
Reactions step is with embodiment 17, and different is is 20h in the reaction times, and product yield is 94%.
The preparation of embodiment 19:N-cyclohexyl-4-amido quinazoline (formula (12))
Reactions step is with embodiment 17, and the consumption of different is ammonium sulfate is 0.08mmol, and product yield is 94%.
The preparation of embodiment 20:N-(1-styroyl)-4-amido quinazoline (formula (13))
Reactions step is with embodiment 1, and different is that benzylamine changes the 1-phenyl-ethyl amine into, and the consumption of reactant is constant, and the reaction times is 13h, and product yield is 95%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：8.66(s，1H)，7.84(d，1H)，7.71-7.75(m，2H)，744-746(m，3H)，730-738(m，2H)，727-729(m，1H)，6.01(d，1H)，5.62-5.68(m，1H)，1.69(d，3H)；
13C?NMR(CDCl
3)δppm：158.6，155.4，149.4，143.2，132.6，128.8，128.6，127.6，126.4，126.0，120.5，114.9，50.2，21.8；
MS(ESI)m/z：250.1(M+H
+)；
IR?v
max(KBr)/cm
-1?3250，3059，2980，1619，1575，1531，1419，1358，1318。
The preparation of embodiment 21:N-(5-methyl isophthalic acid H-pyrazole-3-yl)-4-amido quinazoline (formula (14))
Reactions step is with embodiment 1, and different is that benzylamine changes 5-methyl isophthalic acid H-pyrazoles-3-amine into, and the consumption of 5-methyl isophthalic acid H-pyrazoles-3-amine and hexamethyldisilazane is 0.8mmol, and the reaction times is 14h, and product yield is 83%.
This compound
1H NMR,
13The data of C NMR, HRMS and IR are described below:
1H?NMR(DMSO-d
6)δppm：12.18(br，s，1H)，10.31(br，s，1H)，8.58-8.61(m，2H)，7.74-7.83(m，2H)，7.56(t，1H)，6.58(br，s，1H)，2.27(m，3H)；
13C?NMR(DMSO-d
6)δppm：157.5，155.0，149.8，147.7，139.2，133.3，128.0，126.6，123.7，115.5，98.5，11.5；
HRMS(ESI)m/z：226.1083(M+H
+)，calcd.for?C
12H
12N
5+H
+＝226.1087；
IR?v
max(KBr)/cm
-1?3271，3177，3072，2928，2868，1625，1599，1550，1483，1403，1320。
The preparation of embodiment 22:N-(5-methyl isophthalic acid H-pyrazole-3-yl)-4-amido quinazoline (formula (14))
Reactions step is with embodiment 21, and the consumption of different is 5-methyl isophthalic acid H-pyrazoles-3-amine is 0.8mmol, and the consumption of hexamethyldisilazane is 0.6mmol, and the reaction times is 14h, and product yield is 81%.
The preparation of embodiment 23:N-(5-methyl isophthalic acid H-pyrazole-3-yl)-4-amino-6-methoxyl group quinazoline (formula (15))
Reactions step is with embodiment 21, and different is that quinazoline-4 (3H)-ketone changes 6-methoxyl group quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 18h, and product yield is 81%.
This compound
1H NMR,
13The data of C NMR and MS are described below:
1H?NMR(DMSO-d
6)δppm：12.17(br，s，1H)，10.27(br，s，1H)，8.49(s，1H)，8.05(s，1H)，7.68-7.69(d，1H)，7.43-7.45(d，1H)，6.67(s，1H)，3.92(s，3H)，2.28(s，3H)；
13C?NMR(DMSO-d
6)δppm：157.7，156.8，153.1，148.4，145.4，138.6，129.6，124.7，115.9，102.7，98.3，56.8，11.25；
MS(ESI)m/z：256.1(M+H
+)。
The preparation of embodiment 24:N-(5-methyl isophthalic acid H-pyrazole-3-yl)-4-amino-6-methoxyl group quinazoline (formula (15))
Reactions step is with embodiment 23, and the consumption of different is 5-methyl isophthalic acid H-pyrazoles-3-amine and hexamethyldisilazane is 1.0mmol, and the reaction times is 18h, and product yield is 89%.
The preparation of embodiment 25:N-benzyl-4-amino-2-methyl quinazoline (formula (16))
Reactions step is with embodiment 1, and different is that quinazoline-4 (3H)-ketone changes 2-methyl quinazoline-4 (3H)-ketone into, and the consumption of reactant is constant, and the reaction times is 2.5h, and product yield is 93%.
This compound
1H NMR,
13The data of C NMR, MS and IR are described below:
1H?NMR(CDCl
3)δppm：7.79(d，1H)，7.65-7.70(m，2H)，7.30-7.42(m，6H)，5.94(br，s，1H)，4.88(d，2H)，2.67(s，3H)；
13C?NMR(CDCl
3)δppm：164.5，159.3，150.0，138.5，132.6，128.8，128.2，127.8，127.7，125.1，120.4，112.9，45.2，26.6；
MS(ESI)m/z：250.1(M+H
+)；
IR?v
max(KBr)/cm
-1?3427，3219，3115，1575，1539，1386，1353。
Claims (10)
1. compound method suc as formula the N-substituted-4-amino-quinazoline compound shown in (I); It is characterized in that described method is: is 1: 1～2.5: 1～2.5 to mix suc as formula quinazoline-4 (the 3H)-ketone compounds shown in (II), suc as formula the aminated compounds shown in (III) and hexamethyldisilazane with the ratio of amount of substance; Add the catalyst sulfuric acid ammonium; Being heated with stirring to 105 ℃～125 ℃ under the nitrogen protection reacts; The TLC monitoring is to reacting completely, and after reaction finished, reactant obtained described N-substituted-4-amino-quinazoline compound through separating treatment;
In formula (I) or the formula (II), the benzene ring hydrogen is substituted basic R
1Replace or be not substituted described substituent R
1Be halogen, nitro, C
1～C
4Alkyl or C
1～C
3Alkoxyl group, said halogen is F, Cl, Br or I; R
2Be H, methyl or ethyl; In formula (I) or the formula (III), R
3For 1H-pyrazole-3-yl, the C of the alkyl substituent of C1～C4 are arranged on the benzyl, α-Jia Bianji, 4 or 5
4～C
10Alkyl or C
5～C
8Naphthenic base.
2. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1 is characterized in that said R
1Be methyl, F, Cl, Br, nitro, methoxy or ethoxy.
3. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1 is characterized in that said R
2Be H or methyl.
4. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1 is characterized in that said R
3Be benzyl, α-Jia Bianji, 5-methyl isophthalic acid H-pyrazole-3-yl, 4-methyl isophthalic acid H-pyrazole-3-yl, normal-butyl, isobutyl-, n-hexyl, n-octyl, cyclopentyl or cyclohexyl.
5. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1 is characterized in that said quinazoline-4 (3H)-ketone compounds, aminated compounds are 1: 1.4～2: 1.4～2 with the ratio of the amount of substance of hexamethyldisilazane.
6. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1 is characterized in that the ratio of amount of substance of amount of substance and quinazoline-4 (the 3H)-ketone compounds of said catalyst sulfuric acid ammonium is 5～20: 100.
7. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1 is characterized in that the ratio of amount of substance of amount of substance and quinazoline-4 (the 3H)-ketone compounds of said catalyst sulfuric acid ammonium is 8～12: 100.
8. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1 is characterized in that said temperature of reaction is 120～125 ℃.
9. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1; It is characterized in that said reactants separate treatment process is: after reaction finishes; Reactant is cooled to room temperature, adds methylene dichloride solubilizing reaction thing, carries out column chromatography for separation; Do eluent with sherwood oil and 5: 1 blended mixed solutions of ETHYLE ACETATE volume ratio; TLC detects, and collects the elutriant that contains the N-substituted-4-amino-quinazoline compound, and the elutriant distillation is removed eluent and obtained described N-substituted-4-amino-quinazoline compound.
10. the compound method of N-substituted-4-amino-quinazoline compound according to claim 1; It is characterized in that described method is: is 1: 1.4～2: 1.4～2 to mix suc as formula quinazoline-4 (the 3H)-ketone compounds shown in (II), suc as formula the aminated compounds shown in (III) and hexamethyldisilazane with the ratio of amount of substance, adds ammonium sulfate, and the ratio of described ammonium sulfate and quinazoline-4 (3H)-ketone compounds amount of substances is 8～12: 100; Being heated with stirring to 120～125 ℃ under the nitrogen protection reacts; The TLC monitoring is to reacting completely, and after reaction finished, reactant was cooled to room temperature; Add methylene dichloride solubilizing reaction thing; Carrying out column chromatography for separation, is eluent with sherwood oil and 5: 1 blended mixed solutions of ETHYLE ACETATE volume ratio, and TLC detects; Collection contains the elutriant of N-substituted-4-amino-quinazoline compound, and the elutriant distillation is removed eluent and obtained described N-substituted-4-amino-quinazoline compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102120353A CN101891690B (en) | 2010-06-29 | 2010-06-29 | Synthesis method of N-substituted-4-amino-quinazoline compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102120353A CN101891690B (en) | 2010-06-29 | 2010-06-29 | Synthesis method of N-substituted-4-amino-quinazoline compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101891690A CN101891690A (en) | 2010-11-24 |
| CN101891690B true CN101891690B (en) | 2012-11-14 |
Family
ID=43101063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102120353A Active CN101891690B (en) | 2010-06-29 | 2010-06-29 | Synthesis method of N-substituted-4-amino-quinazoline compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101891690B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103980209B (en) * | 2014-05-21 | 2016-03-09 | 贵州大学 | A kind of 4-N-replaces-5-chloro-quinazoline compounds and preparation method and application |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101547696A (en) * | 2006-08-08 | 2009-09-30 | 奥斯拜客斯制药有限公司 | Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8268843B2 (en) * | 2008-08-29 | 2012-09-18 | Dow Agrosciences, Llc. | 5,8-difluoro-4-(2-(4-(heteroaryloxy)-phenyl)ethylamino)quinazolines and their use as agrochemicals |
-
2010
- 2010-06-29 CN CN2010102120353A patent/CN101891690B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101547696A (en) * | 2006-08-08 | 2009-09-30 | 奥斯拜客斯制药有限公司 | Preparation and utility of substituted quinazoline compounds with alpha-adrenergic blocking effects |
Non-Patent Citations (1)
| Title |
|---|
| 李文举等.4-取代氨基喹唑啉类化合物的研究进展.《精细化工中间体》.2009,第39卷(第3期),15-20. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101891690A (en) | 2010-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011082098A1 (en) | Lysine and arginine methyltransferase inhibitors for treating cancer | |
| WO2011147102A1 (en) | Synthetic method for 6,7-substituents-4-aniline quinazoline | |
| Ren et al. | One-pot synthesis of quinazolin-4 (3H)-ones and fused quinazolinones by a palladium-catalyzed domino process | |
| CN102146060A (en) | Method for preparing gefitinib and intermediate thereof | |
| CN104803918A (en) | Preparation method of enzalutamide | |
| CN104945332A (en) | Preparation method of erlotinib | |
| CN101891690B (en) | Synthesis method of N-substituted-4-amino-quinazoline compound | |
| CN103304492A (en) | Synthesis method of EGFR (epidermal growth factor receptor) inhibitor Dacomitinib | |
| CN103058991A (en) | Preparation method of alpha-crystal form imatinib mesylate | |
| CN105330646A (en) | Preparation method of antineoplastic drug maleic acid neratinib | |
| CN105037236A (en) | Ribociclib intermediate and preparation method thereof | |
| CN106905234B (en) | A method of the synthesis chloro- 6- amino -7- ethoxyquinoline of linatinib intermediate 3- cyano -4- | |
| CN102659629A (en) | Compound and application thereof in preparing erlotinib | |
| CN106045980A (en) | Quinazoline derivative and preparation method thereof | |
| CN102234263B (en) | Method for preparing anti-tumor medicine imatinib | |
| CN101885697A (en) | Preparation method of Oxiracetam, product of Oxiracetam and use of product | |
| CN103232401B (en) | A kind of synthetic method of 4-arylthio quinazoline compounds | |
| CN104003946A (en) | Preparation method for erlotinib hydrochloride impurity | |
| CN109206377B (en) | Novel method for preparing N- (3-chloro-4-fluorophenyl) -7-fluoro-6-nitro-4-quinazolinamine | |
| CN103172575A (en) | Preparation method of one-class 1,3-dipole quinazoline compound | |
| CN106083740A (en) | A kind of 4 anilinoquinazoline derivatives containing 1,2,3 triazoles and preparation method | |
| CN113004212A (en) | Preparation method of dacomitinib | |
| CN101555248B (en) | Method for preparing poly-substituted 1, 5-naphthyridine compound | |
| WO2007000393A1 (en) | 8-alk0xy-4-methyl-3 , 4-dihydr0-quinaz0lin-2-yl amines and their use as 5-ht5a receptor ligands | |
| CN112457243B (en) | Synthesis method of 7-bromo-5-methoxyquinoline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP02 | Change in the address of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: No. 999, Changhong East Street, Deqing County, Huzhou City, Zhejiang Province Moganshan campus, Zhejiang University of Technology Patentee after: ZHEJIANG University OF TECHNOLOGY Address before: Hangzhou City, Zhejiang province 310014 City Zhaohui District Six Patentee before: Zhejiang University of Technology |
|
| EE01 | Entry into force of recordation of patent licensing contract | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20101124 Assignee: Hangzhou Zhiguo Enterprise Service Co.,Ltd. Assignor: JIANG University OF TECHNOLOGY Contract record no.: X2023980033596 Denomination of invention: Synthesis of N-substituted 4-aminoquinazoline derivatives Granted publication date: 20121114 License type: Common License Record date: 20230316 Application publication date: 20101124 Assignee: Hangzhou Guangyoujiu Enterprise Management Partnership (L.P.) Assignor: JIANG University OF TECHNOLOGY Contract record no.: X2023980033595 Denomination of invention: Synthesis of N-substituted 4-aminoquinazoline derivatives Granted publication date: 20121114 License type: Common License Record date: 20230316 Application publication date: 20101124 Assignee: Hangzhou baibeiyou Biotechnology Co.,Ltd. Assignor: JIANG University OF TECHNOLOGY Contract record no.: X2023980033594 Denomination of invention: Synthesis of N-substituted 4-aminoquinazoline derivatives Granted publication date: 20121114 License type: Common License Record date: 20230315 |